Irinotecan therapy in a 12-year-old girl with recurrent brain stem glioma and without functional polymorphisms in UGT1A1 activity: Case report

Kazuhiro Ishikawa, Yasukazu Kajita, Yoshinori Hasegawa, Yukihiro Noda, Jun Yoshida, Toshitaka Nabeshima

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

A 10-year-old girl was diagnosed with astrocytoma grade 2. Immuno-chemo-radiotherapy (interferon, ranimustine, and radiation), second-line chemotherapy (carboplatin and etoposide, 7 cycles) and third-line chemotherapy (ifosfamide, carboplatin, and etoposide) was given to treat progressive disease. Finally, irinotecan therapy was initiated and led to dramatic clinical improvement. Irinotecan is metabolized by carboxylesterase to form an active SN-38, which is further conjugated and detoxified by UDP-glucuronosyltransferase (UGT) to yield its β-glucuronide. The polymorphic UGT isoenzyme, UGT1A1 has genetic variants which decrease in SN-38 glucuronidating capacity and could help predict irinotecan-associated toxicity. The patient suffered excessive toxicity with low-dose irinotecan although no functional polymorphism in UGT1A1 was identified. We suggest that irinotecan offers an effective treatment option for children with recurrent brain stem glioma and other genetic variants except UGT1A1 may be a risk factor for irinotecan-induced toxicity.

Original languageEnglish
Pages (from-to)283-286
Number of pages4
JournalJournal of Neuro-Oncology
Volume74
Issue number3
DOIs
Publication statusPublished - 01-09-2005
Externally publishedYes

Fingerprint

irinotecan
Glioma
Brain Stem
Glucuronosyltransferase
Carboplatin
Etoposide
Therapeutics
Drug Therapy
Carboxylesterase
Ifosfamide
Glucuronides
Astrocytoma

All Science Journal Classification (ASJC) codes

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Cite this

Ishikawa, Kazuhiro ; Kajita, Yasukazu ; Hasegawa, Yoshinori ; Noda, Yukihiro ; Yoshida, Jun ; Nabeshima, Toshitaka. / Irinotecan therapy in a 12-year-old girl with recurrent brain stem glioma and without functional polymorphisms in UGT1A1 activity : Case report. In: Journal of Neuro-Oncology. 2005 ; Vol. 74, No. 3. pp. 283-286.
@article{e0ba931763fd45458f9507762d9f85e7,
title = "Irinotecan therapy in a 12-year-old girl with recurrent brain stem glioma and without functional polymorphisms in UGT1A1 activity: Case report",
abstract = "A 10-year-old girl was diagnosed with astrocytoma grade 2. Immuno-chemo-radiotherapy (interferon, ranimustine, and radiation), second-line chemotherapy (carboplatin and etoposide, 7 cycles) and third-line chemotherapy (ifosfamide, carboplatin, and etoposide) was given to treat progressive disease. Finally, irinotecan therapy was initiated and led to dramatic clinical improvement. Irinotecan is metabolized by carboxylesterase to form an active SN-38, which is further conjugated and detoxified by UDP-glucuronosyltransferase (UGT) to yield its β-glucuronide. The polymorphic UGT isoenzyme, UGT1A1 has genetic variants which decrease in SN-38 glucuronidating capacity and could help predict irinotecan-associated toxicity. The patient suffered excessive toxicity with low-dose irinotecan although no functional polymorphism in UGT1A1 was identified. We suggest that irinotecan offers an effective treatment option for children with recurrent brain stem glioma and other genetic variants except UGT1A1 may be a risk factor for irinotecan-induced toxicity.",
author = "Kazuhiro Ishikawa and Yasukazu Kajita and Yoshinori Hasegawa and Yukihiro Noda and Jun Yoshida and Toshitaka Nabeshima",
year = "2005",
month = "9",
day = "1",
doi = "10.1007/s11060-004-7119-4",
language = "English",
volume = "74",
pages = "283--286",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "3",

}

Irinotecan therapy in a 12-year-old girl with recurrent brain stem glioma and without functional polymorphisms in UGT1A1 activity : Case report. / Ishikawa, Kazuhiro; Kajita, Yasukazu; Hasegawa, Yoshinori; Noda, Yukihiro; Yoshida, Jun; Nabeshima, Toshitaka.

In: Journal of Neuro-Oncology, Vol. 74, No. 3, 01.09.2005, p. 283-286.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Irinotecan therapy in a 12-year-old girl with recurrent brain stem glioma and without functional polymorphisms in UGT1A1 activity

T2 - Case report

AU - Ishikawa, Kazuhiro

AU - Kajita, Yasukazu

AU - Hasegawa, Yoshinori

AU - Noda, Yukihiro

AU - Yoshida, Jun

AU - Nabeshima, Toshitaka

PY - 2005/9/1

Y1 - 2005/9/1

N2 - A 10-year-old girl was diagnosed with astrocytoma grade 2. Immuno-chemo-radiotherapy (interferon, ranimustine, and radiation), second-line chemotherapy (carboplatin and etoposide, 7 cycles) and third-line chemotherapy (ifosfamide, carboplatin, and etoposide) was given to treat progressive disease. Finally, irinotecan therapy was initiated and led to dramatic clinical improvement. Irinotecan is metabolized by carboxylesterase to form an active SN-38, which is further conjugated and detoxified by UDP-glucuronosyltransferase (UGT) to yield its β-glucuronide. The polymorphic UGT isoenzyme, UGT1A1 has genetic variants which decrease in SN-38 glucuronidating capacity and could help predict irinotecan-associated toxicity. The patient suffered excessive toxicity with low-dose irinotecan although no functional polymorphism in UGT1A1 was identified. We suggest that irinotecan offers an effective treatment option for children with recurrent brain stem glioma and other genetic variants except UGT1A1 may be a risk factor for irinotecan-induced toxicity.

AB - A 10-year-old girl was diagnosed with astrocytoma grade 2. Immuno-chemo-radiotherapy (interferon, ranimustine, and radiation), second-line chemotherapy (carboplatin and etoposide, 7 cycles) and third-line chemotherapy (ifosfamide, carboplatin, and etoposide) was given to treat progressive disease. Finally, irinotecan therapy was initiated and led to dramatic clinical improvement. Irinotecan is metabolized by carboxylesterase to form an active SN-38, which is further conjugated and detoxified by UDP-glucuronosyltransferase (UGT) to yield its β-glucuronide. The polymorphic UGT isoenzyme, UGT1A1 has genetic variants which decrease in SN-38 glucuronidating capacity and could help predict irinotecan-associated toxicity. The patient suffered excessive toxicity with low-dose irinotecan although no functional polymorphism in UGT1A1 was identified. We suggest that irinotecan offers an effective treatment option for children with recurrent brain stem glioma and other genetic variants except UGT1A1 may be a risk factor for irinotecan-induced toxicity.

UR - http://www.scopus.com/inward/record.url?scp=26844486583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26844486583&partnerID=8YFLogxK

U2 - 10.1007/s11060-004-7119-4

DO - 10.1007/s11060-004-7119-4

M3 - Article

C2 - 16187025

AN - SCOPUS:26844486583

VL - 74

SP - 283

EP - 286

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 3

ER -